Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Conditions: Advanced or Metastatic Solid Malignancies

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 49

Sponsor: Mirati Therapeutics Inc.

Location: Rocky Mountain Cancer Centers - Littleton Littleton Colorado

Summary

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Eligibility Criteria

Inclusion Criteria: * Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol * Currently tolerating the treatment regimen in the parent protocol * Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest Exclusion Criteria: * Known or suspected presence of other cancer * Other life- threatening illness or organ system dysfunction compromising safety evaluation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04887870). StuddyBuddy aggregates publicly available trial information.